Finally, in March 2020, when the FDA redefined all insulins as biologics, it provided the regulatory framework for biologics and paved the way for interchangeable insulins. This approval granted to Mylan Pharmaceuticals has the potential to lower healthcare costs by competing directly with more expensive branded drugs from the likes of Sanofi and Novo Nordisk. Semglee is priced 20% lower than Lantus, an important cost reduction for patients with diabetes in the United States, who can spend up to $1,000 a month in out-of-pocket costs, even with health insurance.
First interchangeable insulin
- Categories: Fitness / Health
- Tags: diabetesinsulinnaturescience
Related Content
Human Brains May Be Getting Bigger
By
FREE Cape Cod News
April 22, 2024
Healthcare still underprepared for scope of cyber threats, says Kroll report
By
FREE Cape Cod News
April 19, 2024
New bird flu infections: Here’s what you need to know
By
FREE Cape Cod News
April 7, 2024
Lactose Intolerance Impacts Millions in the U.S. — Here's What You Should Know
By
FREE Cape Cod News
February 4, 2024